Seres Therapeutics is a biotechnology company focused on developing innovative therapeutics that harness the power of the microbiome to treat various diseases, particularly gastrointestinal disorders
The company leverages its proprietary platform to identify and develop next-generation microbiome-based treatments, aiming to restore microbial balance in the human body and improve patient outcomes. Through its research and clinical programs, Seres strives to address unmet medical needs with transformative therapies that have the potential to change the standard of care in multiple therapeutic areas.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Seres Therapeutics Inc (NASDAQMCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and to reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients un
U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.63% to 37,445.51 while the NASDAQ fell 0.66% to 14,745.96. The S&P 500 also fell, dropping, 0.55% to 4,737.17.
U.S. stocks traded higher this morning, following the release of jobs report for October. Following the market opening Friday, the Dow traded up 0.50% to 34,009.36 while the NASDAQ rose 1% to 13,427.71. The S&P 500 also rose, gaining, 0.85% to 4,354.30.
